Next-generation mucolytics to treat lung diseases

Next-generation mucolytics to treat lung diseases

Project details

Asthma, cystic fibrosis and COPDs are characterised by the overproduction of mucus, which restricts the airways and makes it difficult for patients to breathe. Thinning this mucus to aid in its clearance, without completely ablating this protective coating of the epithelium, remains a challenging problem in the clinic. 

Mucin proteins, the principle component of mucus, form complex polymeric networks to impart mucus with it high viscosity. Disrupting these intermolecular interactions is an effective means of thinning mucus. 

We are collaborating with the Allan and Czabotar laboratories at the Institute to develop a range of proteins and small molecules to disrupt mucin-mucin interactions to treat diseases of the airways.

About our research group

The Goddard-Borger lab studies the glycobiology of human diseases. 

We are an interdisciplinary group, using techniques in chemical, molecular and cell biology to elucidate the roles of glycoproteins, proteoglycans and glycolipids in the development and progression of diseases as diverse as cancer, asthma, inflammatory bowel diseases and malaria

The lab is comprised of both chemists and biologists, who work close together to enhance each other’s research. It is an ideal fit for anyone interested in doing truly interdisciplinary research in the biomedical sciences.

A notable recent publication from the lab is: Nature Chemical Biology, 2016, 12, 215.

Molecular structure of protein
Coulombic surface of the target protein



Dr Rhys Allan

Dr Rhys Allan
Laboratory Head

Project Type: